Shanghai Race announced that the SR604 injection “hemophilia A/B” indication phase I/II clinical study of the company has reached the main target; recently, the drug clinical trial registration and information disclosure platform of the State Drug Administration published its phase III clinical trial registration information, the trial registration number CTR20263539, and plans to conduct multiple dosage tests with 0.4 mg/kg dosing every 4 weeks.

Shanghai Race announced that the SR604 injection “hemophilia A/B” indication phase I/II clinical study of the company has reached the main target; recently, the drug clinical trial registration and information disclosure platform of the State Drug Administration published its phase III clinical trial registration information, the trial registration number CTR20263539, and plans to conduct multiple dosage tests with 0.4 mg/kg dosing every 4 weeks.